![](/assets/wuxi-biologics-career-german-about-us-1.webp)
![](/assets/wuxi-biologics-career-german-about-us-3.webp)
Our Mission
Every drug can be made and every disease can be treated.
Our mission is to accelerate and transform discovery, development, and manufacturing in the rapidly growing field of biologics to benefit patients worldwide.
We have sites in Ireland, Germany, the United States, China, and Singapore.
We currently employ over 12,000 people and provide services to more than 600 customers worldwide, including all the top 20 biopharmaceutical companies.
Our
German
Sites
German
Sites
DP7 | Leverkusen
Acquired in 2020 from Bayer, the WuXi Biologics Leverkusen facility is a final drug manufacturing plant that offers over 13,000 sq. m. of commercial-scale drug product fill capabilities. This location is home to a growing team of more than 150 scientific staff members. The site achieved its GMP approval for Drug Product manufacturing release in June 2020. Located in the heart of the CHEMPARK Leverkusen, the center of Europe’s chemical market between the high attractive cities of Cologne and Dusseldorf, the facility provides a liquid and lyophilization annual fill capacity of 10 million doses and features a flexible, isolator-based, state-of-the-art Optima filling system. Together with our drug substance facility in nearby Wuppertal we support the whole manufacturing process.
![](/assets/wuxi-career-deko-image-wuppertal-2.jpg)
MFG19 | Wuppertal
The WuXi Biologics Wuppertal site is a state-of-the-art Drug Substance (DS) facility with flexible and open spaces for future expansion. This location is home to a growing team of more than 220 scientific staff members. Ideally located in Wuppertal, an important focal point of Germany’s Pharma industry. The facility offers more than 30,000 sq. m. operating space, including two cell culture suites with 1000L perfusion and 2000L bioreactor capacity, comprised of multiple upstream and downstream suites, integrated laboratory space, and warehouse within building. It is located 38 km from our Leverkusen facility. The Wuppertal facility expects its GMP approval in 2023 to support WuXi Biologics’ Global Dual Source supply chain network strategy which ensures that materials can be sourced, and products can be manufactured at multiple facilities.
![](/assets/wuxi-biologics-standort-2.webp)
Our Country Lead
![](/assets/wuxi-biologics-career-german-ceo-testimonial.webp)
"As Biotech Manager I am passionate about what we do at WuXi Biologics. With our very diverse, highly motivated and excellently trained team we produce life-saving biologics and I am very proud that we can make a difference to many people's life."
Dr. Benjamin Minow, Vice President & Managing Director
Our Timeline
WuXi Biologics has aquired the drug product plant (DP7) in Leverkusen from Bayer AG
Jan 2020
WuXi Biologics has acquired the plant for biological substances (MFG19) in Wuppertal from Bayer AG
May 2021
WuXi Biologics started the renovation of the plant for biological substances (MFG19) in Wuppertal
Aug 2021
DP7 receives GMP inspection for manufacturing approval
Jun 2021
COVID-19 vaccine filled in DP7 for EU countries
Jun 2021
GMP approval of the Wuppertal site (MFG19) is expected for 2023
Aug 2023
Production start/PPQ run at the Wuppertal Site (MFG19)
Dec 2023
Want to find out more about careers at WuXi Biologics?
If you are interested in working with us in the future, please reach out to us by sending your CV or expression of interest to Recruiting_Germany@wuxibiologics.com